Drug intelligence / Profile preview

BVAC-M

Development stage: Preclinical
Lead developer: Cellid
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

BVAC-M is a preclinical-stage therapeutic cancer vaccine being developed by Cellid for the treatment of melanoma. It is built on the company's proprietary CeliVax platform, which utilizes autologous B cells and monocytes as antigen-presenting cells. The vaccine is engineered to target two specific tumor-associated antigens: GP100 (Melanocyte protein PMEL) and MAGE-A3 (Melanoma-associated antigen 3). By presenting these antigens, BVAC-M aims to stimulate a robust T-cell and Natural Killer (NK) cell immune response against melanoma cells.

Targets

MAGEA3 (Melanoma-associated antigen 3)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)

Beyond the preview

Go deeper on BVAC-M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BVAC-M.

Explore the full profile